Intellia Therapeutics and CRISPR Therapeutics Announce U.S. Patent Covering CRISPR/Cas9 Ribonucleoprotein Complexes
CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appeal of CRISPR/Cas9 U.S. Patent Board Decision
Intellia Therapeutics Announces European Patent Office’s Decision to Grant CRISPR/Cas9 Genome Editing Technology Patent
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results
Intellia Therapeutics Demonstrates Pioneering CRISPR/Cas9 Genome Editing Efficiency Data Using Lipid Nanoparticle Delivery Technology
Intellia Therapeutics to Present at March Investor Healthcare Conferences
Intellia Therapeutics to Hold Conference Call to Address Patent Interference Proceedings
CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Provide Update on CRISPR/Cas9 U.S. Patent Interference Proceedings and Grants of Corresponding Patents in the U.K.
Intellia Therapeutics to Present at Leerink Partners 6th Annual Global Healthcare Conference
Intellia Therapeutics Joins Genomics England’s Industry Consortium